Cerebroprotein Hydrolysate
Animal-brain protein hydrolysate containing heterogeneous peptides and amino acids. The studies identified for this exact category are preclinical mouse experiments, so they do not establish human efficacy, dosing, safety, or pharmacokinetics and should not be generalized to separately manufactured products such as Cerebrolysin.
Pharmacokinetic model
A route-level PK model for cerebroprotein hydrolysate is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Peptide Mixture
- Suggested cadence
- once daily
Research behind this entry
-
Cerebroprotein hydrolysate attenuates neurodegenerative changes in Alzheimer's mice model via ferroptosis pathway
Eight APP/PS1 mice received oral cerebroprotein hydrolysate for 90 days and were compared with eight untreated model mice and eight wild-type controls. Behavioral and tissue markers moved in favorable directions, but…
-
Effects and mechanism of cerebroprotein hydrolysate on learning and memory ability in mice
In a scopolamine-induced mouse impairment model, 35 days of treatment changed maze performance, oxidative-stress measures, cholinergic activity, and hippocampal pathology. It is preclinical evidence and does not…
2 published studies referenced in the app, each with a plain-language summary.